Showing results (141-150 of 682) with videos related to
Sort By:
Pageof 69
Expert Review of Hematology|December 14, 2025
Current treatments, practical management, and emerging investigational therapies for myelofibrosisSrinivas Tantravahi, Firas El Chaer, Prithviraj BoseJournal of Hematology & Oncology|August 3, 2012
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsJasleen Randhawa, Alen Ostojic, Radovan Vrhovac, et al.Cancer Control : Journal of the Moffitt Cancer Center|October 9, 2012
Advances in the management of myelofibrosisRami S Komrokji, Srdan Verstovsek, Eric Padron, et al.Seminars in Thrombosis and Hemostasis|July 1, 2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disordersAlfonso Quintás-Cardama, Hagop M Kantarjian, Francis Giles, et al.Expert Review of Hematology|March 17, 2023
Secondary erythrocytosisRodrick Babakhanlou, Srdan Verstovsek, Naveen Pemmaraju, et al.Expert Review of Hematology|May 19, 2015
Ruxolitinib for the treatment of patients with polycythemia veraJean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz, et al.Cancer|July 13, 2006
Role of angiogenesis in chronic lymphocytic leukemiaTomislav Letilovic, Radovan Vrhovac, Srdan Verstovsek, et al.Cancer|December 31, 2015
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapyLorenzo Falchi, Srdan Verstovsek, Farhad Ravandi-Kashani, et al.Toxicon : Official Journal of the International Society on Toxinology|June 5, 2003
Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venomNada Orsolić, Lidija Sver, Srdan Verstovsek, et al.International Journal of General Medicine|February 7, 2014
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomesTariq I Mughal, Kris Vaddi, Nicholas J Sarlis, et al.Pageof 69